| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioCryst Pharmaceuticals, Inc.$10.45
-0.3 (-2.8%)
C 45Pipeline Score Undervalued Biotech · Commercial
Market Cap
2.12 B
EPS
-1.73
P/E Ratio
-4.82 $
Value Trade
34.68 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
156.41 M
R&D Expenses
60.32 M
Operating CF
-61.79 M
Total Assets
465.05 M
Total Liabilities
1.02 B
Equity
-553.84 M
D/E Ratio
12,345
-13.28 %
Week
-3.38 %
1 Month
10.98 %
3 Month
17.92 %
6 Month
-41.21 %
5 Year
32.64 %
All Time
Cash Data
Cash Position
238.40 M
Monthly Burn
20.60 M
Runway
9.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
3.36 M
52 Week Range
6 - 11.31
% held by Insiders
15.44 %
% held by Institutions
84.63 %
Enterprise Value
2.74 B
Total Shares
210.69 M
Short %
18.91 %
Float Shares
199.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioCryst Pharmaceuticals, Inc.
895Total events
7Upcoming
216Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 7
Event history 888
Jun 14, 2026
◆Poster PresentationnavenibartPresentation
Clinical Outcomes with Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
hereditary angioedemasource ↗
Jun 14, 2026
◆Poster PresentationORLADEYOApprovedPresentation
Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
hereditary angioedemasource ↗
Jun 13, 2026
◆Poster PresentationORLADEYOApprovedPresentation
Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
hereditary angioedemasource ↗
Jun 12, 2026
◆Poster PresentationORLADEYOApprovedPresentation
Real-World Patient Characterization, Prior Long-Term Prophylactic Prescribing Patterns, and Treatment Outcomes for Adults on Berotralstat with Hereditary Angioedema in Japan
hereditary angioedemasource ↗
Jun 12, 2026
▲Poster PresentationnavenibartPresentation
Post hoc analysis of ALPHA-STAR study evaluating clinical outcomes across patient subgroups
hereditary angioedemasource ↗
Jun 3, 2026
Jun 2026
▲Enrollment CompletenavenibartTrial
Enrollment completion in ALPHA-ORBIT pivotal study of navenibart
hereditary angioedemasource ↗
May 18, 2026
◆Poster PresentationPresentation
Poster EE69: Healthcare Resource Utilization in Pediatric HAE Patients
hereditary angioedema (HAE)source ↗
May 12, 2026
May 6, 2026
▲First Patient DosedBCX17725Trial
Dosing began in Part 4 of Phase 1 trial of BCX17725
Netherton syndromesource ↗
May 4, 2026
▲Partnership / LicensenavenibartCorporate
European licensing agreement with Neopharmed Gentili for navenibart
hereditary angioedemasource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $2.1B
Pipeline ValueUndervalued
Valuation Signal15
Drugs Scored3.3x
rNPV / MCap Top 67%
Small Cap (rank 302 of 911)
Percentile RankBioCryst Pharmaceuticals, Inc. carries a moderate pipeline score (45/100), with $4.4B risk-adjusted pipeline value, led by Peramivir in Influenza (Phase 3), across $96B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peramivir Small molecule | Seasonal Influenza | Phase 3 | NCT00957996 | 56% | $1.2B | COMPLETED | 234 | - | - | Aug 1, 2011 | - | Feb 12, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ORLADEYO | hereditary angioedema | Phase 1b/2 | 2026-06-12 | HAE attack rate: SOC 0.691 attacks/month (0-5.03), ORLADEYO 0.169 attacks/month (0-1.75); professional care attacks: SOC 22, ORLADEYO 3; attacks during week 37 48: 0 Read More | BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting Read More | |
ORLADEYO | hereditary angioedema | Phase 1b/2 | 2026-06-12 | HAE attack rate: SOC 0.691 attacks/month (0-5.03), ORLADEYO 0.169 attacks/month (0-1.75); professional care attacks: SOC 22, ORLADEYO 3; attacks during week 37 48: 0 Read More | BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting Read More | |
ORLADEYO | hereditary angioedema | Phase 1b/2 | 2026-06-12 | HAE attack rate: SOC 0.691 attacks/month (0-5.03), ORLADEYO 0.169 attacks/month (0-1.75); professional care attacks: SOC 22, ORLADEYO 3; attacks during week 37 48: 0 Read More | BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BCRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BCRXBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Pharmaceuticals presented positive new clinical data for its HAE portfolio, particularly ORLADEYO and the investigational navenibart, at the EAACI Annual Meeting 2026. The data demonstrate significant reductions in HAE attack burden and healthcare utilization among diverse patient populations. The results, particularly from the ALPHA-STAR study, support the potential of navenibart as a long-acting treatment option. No significant safety issues were identified, reinforcing the strength of BioCryst's treatment offerings in hereditary angioedema.
Read more →BCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced the grant of stock options and restricted stock units (RSUs) to nine newly-hired employees as an inducement for their employment. The total granted includes 33,950 stock options and 80,650 RSUs, both effective as of June 1, 2026. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are aimed at fostering long-term employee retention and engagement.
Read more →BCRX▲ +7.7%on this news
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Pharmaceuticals will present seven abstracts related to its hereditary angioedema (HAE) portfolio at the EAACI Annual Meeting in Istanbul from June 12-15, 2026. The presentations will include new clinical trial data for ORLADEYO (berotralstat) and navenibart, highlighting their efficacy in reducing HAE attacks. ORLADEYO is the first oral prophylactic therapy for HAE, while navenibart is under investigation for its long-acting potential.
Read more →BCRX▲ +9.1%on this news
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
BioCryst Pharmaceuticals will present new real-world evidence at the ISPOR 2026 conference, focusing on the healthcare burden of hereditary angioedema in pediatric patients. The studies reveal significant healthcare resource utilization and the impact on caregivers' quality of life. The findings aim to highlight the unmet needs and the necessity for improved disease management.
Read more →BCRXBioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. reported strong financial results for Q1 2026, with ORLADEYO net revenue reaching $148.3 million. The company announced a licensing agreement for navenibart in Europe, providing $70 million upfront with potential milestone payments. BioCryst is making significant progress in pipeline programs, notably on track for regulatory filing for navenibart by late 2027. However, the company recorded a substantial GAAP operating loss primarily due to a special charge related to its acquisition activities.
Read more →BCRXBioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst Pharmaceuticals has entered into a licensing agreement with Neopharmed Gentili, granting exclusive rights to commercialize navenibart for hereditary angioedema in Europe. BioCryst will receive an upfront payment of $70 million and could earn up to $275 million in future milestone payments, along with tiered royalties on sales. The Phase 3 program for navenibart is expected to support a US regulatory filing by the end of 2027.
Read more →BCRXBioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals has announced its participation in two upcoming investor conferences. The first will be at the Bank of America Health Care Conference on May 12, 2026, followed by the Jefferies Global Healthcare Conference on June 3, 2026. The company aims to present its advancements in treatments for hereditary angioedema and other rare diseases.
Read more →BCRXBioCryst to Report First Quarter 2026 Financial Results on May 6
BioCryst Pharmaceuticals, Inc. has announced that it will report its first quarter 2026 financial results on May 6, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. This event highlights BioCryst's ongoing commitment to transparency and communication with stakeholders.
Read more →BCRXBioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as the new Chief Research and Development Officer. Dr. Menon, who previously held a similar role at Alnylam Pharmaceuticals, is expected to lead the company's efforts in advancing its rare disease therapies, particularly the navenibart program. His expertise in managing complex clinical programs and achieving regulatory approvals is anticipated to strengthen BioCryst's strategic direction and R&D capabilities as the company seeks to capitalize on its recent commercial successes. This leadership transition comes at a pivotal time for BioCryst, aiming to enhance its pipeline and overall growth.
Read more →BCRXBioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for 2025, with ORLADEYO net revenue reaching $601.8 million, marking a 38% year-over-year increase. The company achieved profitability for the first time and maintained its revenue guidance for 2026. Additionally, BioCryst received FDA approval for ORLADEYO oral pellets for patients aged 2 to under 12 years and completed the acquisition of Astria Therapeutics.
Read more →BCRXBioCryst to Present at Upcoming Investor Conference
BioCryst Pharmaceuticals announced its participation in the T.D. Cowen 46th Annual Health Care Conference scheduled for March 3, 2026. The presentation will take place at 9:10 a.m. ET, and a live audio webcast will be available on the company's website. BioCryst is known for its focus on developing treatments for hereditary angioedema and other rare diseases.
Read more →BCRXBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Pharmaceuticals will present nine abstracts related to its hereditary angioedema (HAE) portfolio at the upcoming AAAAI Annual Meeting. The presentations will include new clinical trial data for ORLADEYO® and navenibart, with a highlight on positive interim results from the ALPHA-SOLAR trial. The company aims to enhance treatment options for HAE patients.
Read more →BCRXBioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Pharmaceuticals has announced that it will report its fourth quarter 2025 financial results on February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. BioCryst focuses on developing treatments for hereditary angioedema and other rare diseases.
Read more →BCRXBioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics, enhancing its position in the hereditary angioedema market. The acquisition includes navenibart, a promising therapy in Phase 3 development, which could offer improved treatment options for patients. BioCryst also gains Astria's early-stage program for atopic dermatitis, STAR0310.
Read more →BCRXBioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
BioCryst Pharmaceuticals announced preliminary unaudited net revenue of $601 million for ORLADEYO in 2025, a 37% increase from the previous year. The results exceeded prior guidance and reflect strong demand for the treatment. The company also provided an optimistic revenue outlook for 2026, forecasting between $625 million and $645 million in net revenue. Additionally, BioCryst anticipates non-GAAP profitability in 2026 following their upcoming acquisition of Astria Therapeutics, suggesting a robust growth trajectory ahead.
Read more →BCRXBioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals, Inc. has announced its participation at the 44th Annual J.P. Morgan Healthcare Conference, which is scheduled for January 12, 2026. The presentation will take place at 1:30 p.m. ET and will be available for live audio webcast. This event is significant for BioCryst as it represents an opportunity to engage with investors and share updates on its progress.
Read more →BCRXBioCryst Announces FDA Approval of ORLADEYO (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
BioCryst Pharmaceuticals has received FDA approval for ORLADEYO (berotralstat) as the first and only oral prophylactic treatment for pediatric patients aged 2 to less than 12 years with hereditary angioedema (HAE). This oral pellet formulation is designed to improve convenience and compliance by providing a child-friendly method of administration. Positive data from the APeX-P clinical trial demonstrated its safety and efficacy, showcasing reductions in attack rates. This approval aims to address the specific treatment needs of younger children suffering from HAE, a condition often beginning in early childhood.
Read more →BCRX▲ +9.6%on this newsshared move
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
BioCryst Pharmaceuticals, Inc. announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics, Inc. This termination satisfies one of the conditions necessary for the merger's completion. BioCryst anticipates that the merger will finalize in the first quarter of 2026, pending other customary closing conditions. This move underscores BioCryst's commitment to expanding its capabilities in developing treatments for rare diseases.
Read more →BCRXBioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
BioCryst Pharmaceuticals presented new data at the ACAAI meeting, highlighting the psychosocial burden of hereditary angioedema (HAE) on pediatric patients and caregivers. The data from the APeX-P trial indicated that ORLADEYO (berotralstat) demonstrated a sustained reduction in HAE attack rates over one year in children aged 2 to <12. The oral granule formulation is currently under FDA review, with a decision expected by December 2025.
Read more →BCRX▼ -6.3%on this newsshared move
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for Q3 2025, with ORLADEYO net revenue reaching $159.1 million, a 37% increase year-over-year. The company raised its FY 2025 revenue guidance to between $590 million and $600 million and announced a definitive agreement to acquire Astria Therapeutics, expected to close in Q1 2026. The sale of its European ORLADEYO business has strengthened its financial position by allowing debt repayment.
Read more →BCRXBioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
BioCryst Pharmaceuticals announced it will present new pediatric data on ORLADEYO at the ACAAI Annual Scientific Meeting in November 2025. The presentation will include results from the APeX-P trial, focusing on long-term prophylaxis for hereditary angioedema in children aged 2 to under 12. The findings aim to highlight both clinical efficacy and the psychosocial impact of HAE on young patients and caregivers.
Read more →BCRXBioCryst to Report Third Quarter 2025 Financial Results on November 3
BioCryst Pharmaceuticals has announced that it will report its financial results for the third quarter of 2025 on November 3, 2025. The company plans to host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide corporate updates. Further details about accessing the call will be available on the company's website.
Read more →BCRX▼ -8.8%on this news
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals has announced its acquisition of Astria Therapeutics, aiming to enhance its portfolio in hereditary angioedema (HAE) with the addition of navenibart, a late-stage plasma kallikrein inhibitor. The deal, valued at approximately $920 million, is expected to close in the first quarter of 2026, pending regulatory approvals. This acquisition is anticipated to solidify BioCryst's growth trajectory in the HAE market.
Read more →BCRX▼ -8.8%on this newsshared move
VOTING AND SUPPORT AGREEMENT among BIOCRYST PHARMACEUTICALS, INC. and certain stockholders of ASTRIA THERAPEUTICS, INC. Dated as of
BioCryst Pharmaceuticals, Inc. has entered into a Voting and Support Agreement with certain shareholders of Astria Therapeutics, Inc. The agreement, dated October 14, 2025, outlines the stockholders' commitment to support a merger between BioCryst and Astria. During the agreement period, stockholders will vote in favor of the merger and related transactions, solidifying collaborative intentions for the future of both companies.
Read more →BCRXBioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
BioCryst Pharmaceuticals has completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with the potential for an additional $14 million in milestones. This strategic move allows BioCryst to concentrate on U.S. sales, significantly improving its operating margin and cash flow. The company remains optimistic about reaching its financial targets for 2025.
Read more →BCRXBioCryst Announces Departure of Dr. Helen Thackray
BioCryst Pharmaceuticals has announced the departure of Dr. Helen Thackray, the company’s chief research and development officer, who will transition into an advisory role until the end of the year. She joined BioCryst in 2019 and has played a key role in advancing several critical programs, including the BCX17725 inhibitor for Netherton syndrome. Thackray's decision to leave is to pursue another leadership opportunity as the company recently completed a CEO succession process, which she was a finalist in. This change in leadership may raise questions about project stability and the future direction of BioCryst's pipeline.
Read more →BCRX▲ +9.8%on this newsshared move
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for Q2 2025, with ORLADEYO net revenue reaching $156.8 million, a 45% increase compared to the same quarter last year. The company also recorded an operating profit of $29.8 million, marking a significant growth of 239% year-over-year. Additionally, BioCryst plans to retire its remaining term debt following the sale of its European ORLADEYO business, further strengthening its financial position. The company maintains its guidance for full-year 2025 revenues between $580 million and $600 million, despite the upcoming divestiture.
Read more →BCRXBioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
BioCryst Pharmaceuticals has announced the retirement of CEO Jon Stonehouse, effective December 31, 2025, and the appointment of Charlie Gayer as his successor. Gayer, currently the Chief Commercial Officer, will officially assume the CEO role on January 1, 2026. He has been key in the successful launch of ORLADEYO, which is expected to reach peak sales of $1 billion. This leadership transition reflects the company's confidence in Gayer's ability to continue driving success and value for stakeholders.
Read more →BCRXBioCryst to Report Second Quarter 2025 Financial Results on August 4
BioCryst Pharmaceuticals, Inc. will announce its second quarter 2025 financial results on August 4, 2025. The company's management will conduct a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. The call will be accessible to domestic and international callers.
Read more →BCRXBioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
BioCryst Pharmaceuticals will present its research focused on hereditary angioedema (HAE) during the 2025 US HAEA National Summit in Baltimore. The findings highlight the challenges faced by pediatric patients under 12 years old and their caregivers in managing HAE. The company aims to better understand patient perspectives to enhance treatment options. CEO Jon Stonehouse will also engage with the HAE community during the summit, emphasizing BioCryst's commitment to improving patient care.
Read more →BCRXBioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
BioCryst Pharmaceuticals has appointed Babar Ghias as Chief Financial Officer and Head of Corporate Development. Ghias joins from AvenCell Therapeutics, bringing a wealth of experience in financial leadership in the biopharma sector. His background includes successfully launching multiple biotechnology companies and raising substantial capital. This leadership change is seen as pivotal for BioCryst's growth strategy, especially with their current commercial momentum and advancing pipeline initiatives.
Read more →BCRXBioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million
BioCryst Pharmaceuticals announced the sale of its European ORLADEYO business to Neopharmed Gentili for up to $264 million, comprising a $250 million upfront payment and potential future milestones. The funds will be used to eliminate $249 million in term debt, thus saving the company approximately $70 million in interest payments over time. BioCryst anticipates ending 2027 with $700 million in cash and no debt, which represents a significant improvement on previous forecasts. This transaction is expected to enhance BioCryst's profitability and facilitate continued growth for ORLADEYO in Europe.
Read more →BCRXBioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI
BioCryst Pharmaceuticals presented new data on ORLADEYO (berotralstat) at the EAACI meeting, highlighting its long-term efficacy and safety for hereditary angioedema (HAE) treatment across all age groups. Studies demonstrated significant reductions in HAE attack frequency and improvements in patient quality of life. Patients reported enhanced daily functioning and emotional well-being with ongoing berotralstat treatment. However, caution is advised regarding potential dosage-related risks, particularly concerning QT prolongation and drug interactions.
Read more →BCRXBioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
BioCryst Pharmaceuticals announced that ORLADEYO (berotralstat) has obtained reimbursement approval in the Netherlands, facilitating access across all major European countries for patients aged 12 and older with hereditary angioedema (HAE). This approval follows the European Commission's marketing authorization from April 2021 and signifies a significant advancement for the treatment of HAE, which is the first oral, once-daily preventive therapy available. The drug is commercially available in over 30 countries. However, there are safety concerns regarding QT prolongation at higher doses and insufficient data on pediatric and pregnancy use.
Read more →BCRXBioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
BioCryst Pharmaceuticals announced that it will present new data on its oral treatment ORLADEYO (berotralstat) for hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology meeting in Glasgow from June 13-16, 2025. Four abstracts highlighting the treatment's impact on patients' quality of life, perceptions, effectiveness, and pediatric usage will be showcased. The research aims to underscore the benefits of ORLADEYO as a preventative therapy for HAE, particularly in reducing attacks requiring treatment. However, the safety of the drug for treating acute attacks remains unverified.
Read more →BCRXBioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages
BioCryst Pharmaceuticals announced promising new data showing that its oral therapy, ORLADEYO (berotralstat), significantly reduces hereditary angioedema (HAE) symptoms across various age groups. The findings, presented at a workshop in Budapest, indicate that children initiating treatment reported fewer days with HAE symptoms. Additionally, the data revealed improvements in disease control and quality of life for patients participating in expanded access programs. Despite its positive profile, safety concerns regarding dosage and limited data on specific populations remain.
Read more →BCRXBioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat)
BioCryst Pharmaceuticals presented new real-world evidence demonstrating that their oral medication ORLADEYO (berotralstat) significantly reduces hereditary angioedema (HAE) attack rates in adolescents and adults with severe HAE. The study, shared at the ISPOR 2025 conference, followed patients for 18 months post-treatment initiation, revealing marked decreases in attack frequency compared to baseline levels. This data suggests enhanced treatment outcomes for these patient populations, emphasizing the potential of ORLADEYO in managing HAE effectively.
Read more →BCRXBioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
BioCryst Pharmaceuticals has announced that the FDA has accepted its NDA for the oral granules of ORLADEYO (berotralstat) for use in children aged 2 to 11 with hereditary angioedema (HAE). This application has been granted Priority Review, with a target action date set for September 12, 2025. If approved, ORLADEYO would be the first targeted oral prophylactic therapy available specifically for this pediatric population. Positive interim clinical trial results indicated that ORLADEYO was well tolerated, showcasing its potential to improve management of HAE in younger patients.
Read more →BCRX▲ +23.5%on this news
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for Q1 2025, with ORLADEYO net revenues reaching $134.2 million, a 51% increase year-over-year. The company raised its full-year revenue guidance to between $580 million and $600 million, expecting to become profitable in 2025. Additionally, BioCryst submitted a new drug application for ORLADEYO oral granules for children with hereditary angioedema and opened an investigational new drug application for its treatment of Netherton syndrome. Overall, the company demonstrated solid progress across its product pipeline and financial health.
Read more →BCRXBioCryst Appoints Steve Frank to Board of Directors
BioCryst Pharmaceuticals has appointed Steve Frank, a prominent healthcare investment banking leader, to its board of directors. Mr. Frank brings a wealth of experience from his tenure at J.P. Morgan and Bear Stearns, and is expected to contribute significantly to the company's strategic objectives. His appointment comes at a pivotal time for BioCryst, as it advances towards profitability and new product development while handling its existing commercial product, ORLADEYO. The company believes it is in a strong position within the biopharma sector, with promising prospects for sustainable growth.
Read more →BCRXBioCryst to Report First Quarter 2025 Financial Results on May 5
BioCryst Pharmaceuticals, Inc. has announced the date for its first quarter 2025 financial results, which will be reported on May 5, 2025. The company will also hold a conference call and webcast at 8:30 a.m. ET to discuss these results and provide an update on corporate affairs. Interested participants can access the conference call via specific phone numbers for domestic and international callers, or they can opt for the online webcast. The financial results and corporate updates are key events for stakeholders.
Read more →BCRX▼ -10%on this news
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
BioCryst Pharmaceuticals (BCRX) announced strong financial results for Q4 2024, reporting ORLADEYO revenues of $124.2 million, marking a 36.6% increase year-over-year. The company raised its revenue guidance for FY 2025 to between $535-$550 million. BioCryst also highlighted plans for pediatric label expansion for ORLADEYO and initial clinical data from two pipeline drugs expected by year-end. Despite reporting an operating loss, the company is optimistic about achieving profitability and positive cash flow by the second half of 2025.
Read more →BCRX▼ -10%on this news
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
BioCryst Pharmaceuticals reported positive interim results from the APeX-P trial assessing ORLADEYO (berotralstat) for pediatric hereditary angioedema patients aged 2 to under 12 years. The drug was found to be safe and well tolerated, achieving significant reductions in monthly attack rates, with median rates dropping to zero after one month of treatment. BioCryst plans to submit a New Drug Application to the FDA later this year, aiming to address the unmet needs of children with HAE.
Read more →BCRXBioCryst Launches ORLADEYO (berotralstat) in Portugal
BioCryst Pharmaceuticals has announced the launch of ORLADEYO (berotralstat) in Portugal, following a recommendation from Infarmed for its use in preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older. This marks a significant advancement in treatment options for HAE patients, as ORLADEYO is the first oral medication available for this condition. The drug is already licensed in 44 countries following prior European Commission marketing authorization.
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
BioCryst Pharmaceuticals announced plans to present five abstracts about ORLADEYO (berotralstat) at the upcoming 2025 AAAAI/WAO congress in San Diego. Notably, one of the abstracts will detail the results from the APeX-P trial, which assesses the oral treatment's efficacy in pediatric patients aged 2 to <12 years. The congress will take place from February 28 to March 3, 2025, potentially providing valuable insights into ORLADEYO's role in managing hereditary angioedema in younger patients.
Read more →BCRXBioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BioCryst Pharmaceuticals, Inc. has announced that it will report its fourth quarter financial results for 2024 on February 24, 2025. Management will hold a conference call at 8:30 a.m. ET to discuss these results and provide updates about the company. Both a live call and a webcast will be available to the public and investors following the announcement.
Read more →BCRXBioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
BioCryst Pharmaceuticals announced positive preliminary financial results for ORLADEYO for the full year 2024, with net revenues projected at $437 million, a 34% increase from the previous year. The company anticipates further growth, forecasting net revenues for 2025 to be between $515 million and $535 million. In addition to financial growth, BioCryst plans to broaden the ORLADEYO label for pediatric patients and advance other pipeline candidates, indicating a strong outlook for continued success. Overall, the company aims for potential profitability and positive cash flow by the second half of 2025.
Read more →BCRXBioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals, Inc. has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2025, in San Francisco. The presentation will be available via a live audio webcast on the company's website. This event is significant as it allows BioCryst to discuss its latest developments and strategies with a wide audience of investors and industry leaders.
Read more →BCRXBioCryst Launches ORLADEYO (berotralstat) in Ireland
BioCryst Pharmaceuticals has launched ORLADEYO (berotralstat) in Ireland following a recommendation from the Health Services Executive (HSE) for its use in preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. This therapy is notable as the first oral, once-daily treatment for HAE, enhancing the options available for patients and prescribers. ORLADEYO is already licensed in 44 countries and was previously authorized by the European Commission in April 2021. However, there are important safety considerations, including risks related to dosage and unestablished efficacy for acute attacks.
Read more →BCRX▼ -12.8%on this newsshared move
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for Q3 2024, with ORLADEYO net revenue increasing by 35.7% year-over-year to $116.3 million. The company also posted a GAAP operating profit of $7.7 million, highlighting growth and demand for its products. The full-year revenue guidance for ORLADEYO has been adjusted upward to a range of $430-$435 million. Furthermore, BioCryst's pipeline is advancing with BCX17725 now in clinical trials for Netherton syndrome, a rare genetic condition with no currently approved treatments.
Read more →BCRXBioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO (berotralstat)
BioCryst Pharmaceuticals announced new real-world evidence demonstrating high adherence and persistence rates for ORLADEYO (berotralstat) in patients with hereditary angioedema (HAE). The study highlighted significant reductions in HAE attack rates after patients initiated treatment with ORLADEYO, which compares favorably with other long-term prophylactic therapies. Patient surveys revealed a strong preference for oral administration over injectable options, suggesting a positive outlook for ORLADEYO's adoption in clinical practice.
Read more →BCRXBioCryst to Report Third Quarter 2024 Financial Results on November 4
BioCryst Pharmaceuticals, Inc. has announced that it will report its financial results for the third quarter of 2024 on November 4, 2024. The company's management will conduct a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide updates on corporate developments. This announcement follows standard practice as companies prepare to share their financial data with stakeholders.
Read more →BCRXBioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO (berotralstat)
BioCryst Pharmaceuticals presented new real-world evidence supporting the efficacy of ORLADEYO (berotralstat) in patients with hereditary angioedema (HAE). The study showed significant reductions in healthcare resource utilization, including a 34% decrease in all-cause hospitalizations and a 52% reduction in angioedema-related hospitalizations. Additionally, notable decreases in healthcare visits related to HAE attacks were documented. This data will be presented at the AMCP Nexus 2024 meeting in Las Vegas from October 14-17, 2024.
Read more →BCRXBioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
BioCryst Pharmaceuticals announced presentations related to ORLADEYO (berotralstat) at the upcoming American College of Allergy, Asthma & Immunology annual meeting. The presentations will showcase real-world evidence reflecting patient adherence, sustained attack reductions, and patient preferences for the oral prophylactic treatment of hereditary angioedema. The data supports the effectiveness and patient satisfaction associated with ORLADEYO as a once-daily therapy for patients aged 12 and older. The meeting is scheduled to take place in Boston between October 24-28, 2024, with abstracts accessible online for registered attendees.
Read more →BCRXBioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
BioCryst Pharmaceuticals has commenced enrollment in a Phase 1 trial for BCX17725, a KLK5 inhibitor aimed at treating Netherton syndrome, an ultra-rare genetic disorder. This marks the company's first protein therapeutic to enter clinical trials. The trial will evaluate the safety and efficacy of BCX17725, with initial results anticipated by the end of 2025. Netherton syndrome currently lacks approved treatment options, highlighting the importance of this investigational therapy in addressing critical patient needs.
Read more →BCRXBioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BioCryst Pharmaceuticals has announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance to make ORLADEYO (berotralstat) accessible through Canada's public healthcare system. This once-daily oral therapy is approved for the routine prevention of hereditary angioedema attacks in patients aged 12 and older. BioCryst aims to partner with provincial drug plans to ensure ORLADEYO is included in public formularies, enhancing access for HAE patients across Canada. The negotiations followed positive recommendations from Canadian regulatory agencies, marking significant progress for BioCryst's mission to provide necessary therapies for HAE management.
Read more →BCRXBioCryst Presents New ORLADEYO (berotralstat) Data at 7th Bradykinin Symposium
BioCryst Pharmaceuticals presented new data on ORLADEYO (berotralstat) at the 7th Bradykinin Symposium in Berlin, highlighting interim results from the APeX-N trial. The study, which involved 56 patients across several European countries, focused on assessing the safety and efficacy of berotralstat in routine clinical use for hereditary angioedema (HAE). Additionally, discussions on shared decision-making between healthcare providers and patients provided insights into improving management strategies for HAE. However, some patients experienced adverse effects, and treatment discontinuations were noted.
Read more →BCRXBioCryst Appoints Dr. Donald Fong Chief Medical Officer
BioCryst Pharmaceuticals has appointed Dr. Donald Fong as the new chief medical officer, effective immediately. Dr. Fong brings over 25 years of clinical experience, previously overseeing clinical development at Annexon Biosciences and leading initiatives at Kaiser Permanente. The appointment aligns with BioCryst's commitment to developing therapies for significant unmet medical needs, including Netherton syndrome and diabetic macular edema. He is expected to play a crucial role in the company’s global medical team moving forward.
Read more →BCRX▲ +7%on this news
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported a strong second quarter for 2024, with ORLADEYO net revenue increasing by 34% year-over-year to $108.3 million. The company also raised its full-year revenue guidance from $390-$400 million to $420-$435 million, reflecting strong market demand. However, it announced the discontinuation of its oral Factor D inhibitor, BCX10013, due to inadequate clinical efficacy. While the overall financial results showed progress with an operating profit of $8.8 million, the rising operational costs pose potential challenges ahead.
Read more →BCRXBioCryst to Report Second Quarter 2024 Financial Results on August 5
BioCryst Pharmaceuticals, Inc. announced that it will report its second quarter financial results on August 5, 2024. The company plans to host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access this information via telephone or online on the company’s website.
Read more →BCRX▲ +5.1%on this newsshared move
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO (berotralstat) Treatment
BioCryst Pharmaceuticals presented new data at the EAACI Congress showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor levels experienced a significant reduction in monthly attack rates after starting treatment with ORLADEYO (berotralstat). In a cohort of six patients, five achieved a 75 to 100 percent reduction in attack rates within six months. While five patients reported no adverse events, one experienced mild gastrointestinal symptoms which did not necessitate discontinuation of the treatment. The study underscores the need for safer and more effective prophylactic treatments for HAE.
Read more →BCRXBioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
BioCryst Pharmaceuticals announced it will present new data on its oral drug ORLADEYO (berotralstat) at the upcoming European Academy of Allergy and Clinical Immunology meeting in Valencia from May 31 to June 3, 2024. The presentations will include research on the drug's effectiveness in patients with hereditary angioedema and insights from patient and physician perspectives. ORLADEYO is the first oral therapy aimed at preventing hereditary angioedema attacks, although its safety profile reveals risks, particularly at higher dosages. The safety for use in younger populations and pregnant individuals remains unspecified.
Read more →BCRXBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat)
BioCryst Pharmaceuticals presented real-world evidence at the 2024 ISPOR conference showing that patients with hereditary angioedema (HAE) experience significant reductions in healthcare resource utilization after starting ORLADEYO (berotralstat). The study, based on data from patients who initiated treatment between December 2020 and December 2022, highlighted notable decreases in all-cause and angioedema-related hospitalizations and outpatient visits. This evidence supports ORLADEYO's effectiveness not only in reducing HAE morbidity but also in being a cost-efficient management option for both patients and payers.
Read more →BCRX▲ +18.4%on this newsshared move
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong financial results for Q1 2024, with ORLADEYO revenue increasing by 30% year-over-year to $88.9 million. The company has adjusted its full-year revenue guidance upward to $390-$400 million and noted the positive momentum in its pipeline programs, including BCX17725 and avoralstat, which are on track for clinical trials. However, the company still recorded a net loss of $35.4 million, indicating ongoing financial challenges despite the revenue growth.
Read more →BCRXBioCryst to Report First Quarter 2024 Financial Results on May 6
BioCryst Pharmaceuticals, Inc. has announced that it will report its financial results for the first quarter of 2024 on May 6, 2024. The management team will host a conference call and a webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. The call will be accessible for both domestic and international audiences, and a replay will be available on the company’s website.
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals has announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ORLADEYO (berotralstat) for the prevention of hereditary angioedema (HAE) attacks. This approval is viewed as a significant advancement for patients in Brazil, providing them access to a daily oral prophylactic therapy. The company has partnered with Pint Pharma GmbH for commercializing ORLADEYO across Latin America. However, there are established safety concerns with the drug, particularly related to dosage limits and unverified efficacy in acute cases.
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
BioCryst Pharmaceuticals reported strong financial results for Q4 and full year 2023, highlighted by a significant increase in ORLADEYO net revenue, reaching $90.9 million in Q4. The company anticipates 2024 ORLADEYO net revenue between $380-$400 million and aims for an operating profit in 2024, with a positive cash flow expected by the second half of 2025. Noteworthy is the growth in the patient base and prescribers, alongside launches in new international markets. However, the company continues to operate at a loss, clocking a net loss of $61.7 million for Q4 2023.
Read more →BCRXBioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment
BioCryst Pharmaceuticals announced new real-world data showing that ORLADEYO (berotralstat) significantly reduces HAE attack rates in patients over 18 months. These findings, presented at the 2024 AAAAI annual meeting, indicate substantial improvements across various patient demographics, including those with differing baseline severities and prior prophylaxis experiences. The data demonstrate low discontinuation rates and high patient adherence to treatment, suggesting ORLADEYO's effectiveness in managing HAE attacks. The results encourage further investigation into its long-term benefits and overall safety profile.
Read more →BCRXBioCryst Launches ORLADEYO (berotralstat) in Italy
BioCryst Pharmaceuticals announced the launch of ORLADEYO (berotralstat) in Italy following a positive recommendation from the Italian Medicines Agency (AIFA). The drug is approved for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older. This marks the introduction of the first oral, once-daily therapy for this condition in Italy, promoting greater access to modern treatment options for patients and clinicians. This launch follows the European Commission's marketing authorization granted in April 2021.
Read more →BCRXBioCryst to Report Fourth Quarter 2023 Financial Results on February 26
BioCryst Pharmaceuticals, Inc. has announced the date for its fourth quarter 2023 financial results, which will be reported on February 26, 2024. The company will also host a conference call and webcast at 8:30 a.m. ET to go over these results and provide a corporate update. Investors can access the live call via specific phone numbers or through the company's website.
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Pharmaceuticals, Inc. announced that it will present five abstracts on ORLADEYO (berotralstat) at the 2024 AAAAI annual meeting. The research focuses on real-world outcomes, tolerability, and effectiveness of ORLADEYO in treating hereditary angioedema in patients aged 12 years and older. The findings contribute to the understanding of ORLADEYO's role in prophylaxis and patient adherence. These presentations are expected to enhance the dialogue on advancing treatment options in the allergy and immunology fields.
Read more →BCRX▼ -5.7%on this news· ran to +18% by day 1
BioCryst Announces Preliminary Full Year 2023 ORLADEYO (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
BioCryst Pharmaceuticals reported a preliminary net revenue of $325 million for 2023 for its drug ORLADEYO, a 29% increase year-on-year. The company projects revenue growth to between $380 million and $400 million in 2024, while also forecasting an operating profit for the year. With a clear path towards achieving $1 billion in peak sales and positive cash flow expected by the second half of 2025, BioCryst remains optimistic about its future performance despite potential uncertainties. Moreover, the company plans to reduce its R&D expenses and has outlined the possible out-licensing of its Factor D inhibitor, BCX10013, to further enhance its commercialization strategy.
Read more →BCRXBioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals, Inc. has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2024, at 6:00 p.m. ET in San Francisco. This conference is significant within the healthcare sector, providing a platform for companies to present their strategies and updates. Interested parties can access the live audio webcast and replay through the company's official website.
Read more →BCRXBioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO (berotralstat)
BioCryst Pharmaceuticals has published data from the open-label extension of the APeX-2 trial for its drug ORLADEYO, used to treat hereditary angioedema (HAE) in patients aged 12 and older. The data indicates long-term use of ORLADEYO leads to a significant reduction in HAE attacks and enhances patients' quality of life. The findings were published in the Journal of Allergy and Clinical Immunology: In Practice, emphasizing ORLADEYO's safety and effectiveness. The study adds further evidence supporting ORLADEYO as a viable treatment option for managing HAE.
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
BioCryst Pharmaceuticals has received approval from Argentina's ANMAT for ORLADEYO (berotralstat) to prevent hereditary angioedema (HAE) attacks in adults and children aged 12 and older. This marks a significant advancement in offering patients a convenient, once-a-day oral therapy. The approval supports BioCryst's strategy to expand ORLADEYO's availability across Latin America through a partnership with Pint Pharma. However, the therapy is not intended for treating acute HAE attacks, and there are concerns regarding its safety profile and potential market challenges.
Read more →BCRX▼ -5.6%on this news
BioCryst Launches ORLADEYO (berotralstat) in Spain
BioCryst Pharmaceuticals has received marketing authorization from the Spanish Ministry for Health for its drug ORLADEYO (berotralstat), designed for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older. The company is optimistic about the impact this first oral, once-daily therapy will have on patients and healthcare providers in Spain. However, BioCryst has acknowledged potential risks related to the commercialization process and ongoing uncertainties due to external factors like the COVID-19 pandemic.
Read more →BCRXBioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO (berotralstat)
BioCryst Pharmaceuticals has presented new data indicating that ORLADEYO (berotralstat) significantly reduces the monthly attack rates in patients with hereditary angioedema (HAE) who have normal C1-inhibitor levels. The findings, based on real-world analyses, were shared at the 2023 ACAAI meeting and suggest that long-term prophylaxis with this oral therapy offers a meaningful benefit for affected patients. Additionally, a post-hoc analysis from a prior clinical trial reinforces these results, highlighting the considerable impact of ORLADEYO on disease burden and patient quality of life.
Read more →BCRX▲ +7.1%on this newsshared move
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector
BioCryst Pharmaceuticals has partnered with Clearside Biomedical to develop avoralstat, a plasma kallikrein inhibitor, for treating diabetic macular edema (DME). Utilizing Clearside's proprietary SCS Microinjector, avoralstat will be delivered directly to the back of the eye, potentially improving efficacy for patients who do not respond to conventional anti-VEGF therapies. BioCryst will pay Clearside an upfront fee of $5 million, with additional milestone payments tied to the development and sales of avoralstat. Both companies emphasize their commitment to addressing the unmet needs of DME patients.
Read more →BCRX▲ +7.1%on this newsshared move
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
BioCryst Pharmaceuticals highlighted its expanding pipeline of first-in-class therapies during its R&D Day. The company announced plans to initiate clinical trials for five new programs targeting various complement-mediated diseases over the next 24 months, including a fusion protein for Netherton syndrome and an oral C5 inhibitor for generalized myasthenia gravis. BioCryst aims to leverage its experience and innovative drug design capabilities to deliver effective treatments and improve patient outcomes. The anticipated clinical developments reflect the company's strategic focus on addressing unmet medical needs in rare diseases.
Read more →BCRXBioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong third quarter results with ORLADEYO net revenue of $85.7 million, marking a 29.8% year-over-year increase. The company anticipates at least $320 million in total ORLADEYO revenue for 2023 and aims for peak revenue of $1 billion. Despite a net loss of $36.1 million, which is an improvement from the prior year's loss, the firm is focused on patient growth and global market expansion. BioCryst will host an R&D Day on November 3, 2023, to discuss its drug discovery process and future therapies in development.
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
BioCryst Pharmaceuticals announced plans to present two abstracts on ORLADEYO (berotralstat) at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology. The abstracts will focus on the drug's effectiveness in reducing attack rates in patients with hereditary angioedema. The presentations will take place between November 9-13, 2023, in Anaheim, California. ORLADEYO is an oral therapy indicated for the prophylactic treatment of hereditary angioedema in patients 12 years and older.
Read more →BCRXBioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
BioCryst Pharmaceuticals has initiated enrollment in a proof-of-concept trial for BCX10013, an oral Factor D inhibitor aimed at treating complement-mediated diseases. The trial will evaluate the safety and efficacy of once-daily dosing in patients with paroxysmal nocturnal hemoglobinuria (PNH). The company aims to develop a differentiated treatment that addresses significant unmet medical needs within this patient population. Future advancement into pivotal trials may occur if BCX10013 demonstrates its potential as a best-in-class therapy based on trial outcomes.
Read more →BCRXBioCryst to Host R&D Day on November 3
BioCryst Pharmaceuticals has announced an R&D Day set for November 3, 2023, at 1:00 p.m. ET. The event will highlight the company's drug discovery process and introduce new therapies from its pipeline. It will be held at their Discovery Center of Excellence in Birmingham, Alabama, and will also be available via live webcast. Attendance is limited to confirmed invited guests.
Read more →BCRXBioCryst to Report Third Quarter 2023 Financial Results on November 2
BioCryst Pharmaceuticals, Inc. announced it will report its third quarter 2023 financial results on November 2, 2023. The management will host a conference call at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. The event will be accessible for domestic and international callers, and a live webcast will be available on the company's website. BioCryst focuses on developing innovative medicines for rare diseases and has several active programs underway.
Read more →BCRXBioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported its financial results for Q2 2023, showcasing significant growth in ORLADEYO revenues, which reached $81.0 million, a rise of 24% from the previous year. The company is on track to achieve its revenue goal of at least $320 million for the full year. However, it also reported a net loss of $75.3 million during the quarter. Looking ahead, BioCryst plans to host an R&D day on November 3, 2023, to introduce new pipeline assets and updates.
Read more →BCRXBioCryst to Report Second Quarter 2023 Financial Results on August 3
BioCryst Pharmaceuticals has announced that it will report its second quarter 2023 financial results on August 3, 2023. Management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. The company is known for developing small-molecule medicines for rare diseases and has approved treatments like ORLADEYO® and RAPIVAB® in various markets.
Read more →BCRXBioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO (berotralstat) in Turkey
BioCryst Pharmaceuticals has formed a partnership with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration marks BioCryst's sixth global distribution agreement for the oral therapy designed to prevent attacks of hereditary angioedema. Er-Kim, known for its experience in rare disease therapies, will leverage its distribution capabilities to enhance access for patients in this important market. However, the article also outlines safety concerns associated with the drug, including QT prolongation at higher dosages and the unestablished efficacy for acute HAE attacks.
Read more →BCRXBioCryst to Participate in the 2023 US HAEA National Summit
BioCryst Pharmaceuticals announced its participation in the 2023 US HAEA National Summit, showcasing three abstracts related to ORLADEYO, an oral treatment for hereditary angioedema. The summit will take place in Orlando, Florida from July 20-23, 2023. CEO Jon Stonehouse expressed enthusiasm for re-engaging with the HAEA community. While ORLADEYO offers innovative treatment options, there are notable safety considerations, including risks associated with dosage and potential adverse reactions.
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
BioCryst Pharmaceuticals announced the presentation of new data on ORLADEYO (berotralstat) at the upcoming 2023 European Academy of Allergy and Clinical Immunology Congress in Hamburg, Germany. Two abstracts will showcase the drug's effectiveness in reducing hereditary angioedema (HAE) attack rates and improving quality of life for patients. ORLADEYO is the first oral treatment specifically designed for HAE prophylaxis in patients aged 12 and older. While the findings are promising, there are noted safety considerations associated with dosage and lack of established efficacy for acute attacks.
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile
BioCryst Pharmaceuticals announced that the Public Health Institute of Chile has granted marketing authorization for ORLADEYO (berotralstat), an oral medication for the prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This approval marks a significant milestone as it is the first authorization for ORLADEYO in Latin America. BioCryst has collaborated with Pint Pharma GmbH to register and promote ORLADEYO across the pan-Latin America, focusing on addressing the needs of HAE patients in the region. Despite the positive approval, it is noted that the drug's safety and efficacy have not been established for acute HAE attacks.
Read more →BCRX▲ +12.5%on this newsshared move
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
BioCryst Pharmaceuticals (BCRX) reported significant financial results for Q1 2023, highlighting a 38% year-over-year growth in ORLADEYO net revenue to $68.4 million. The company also noted a 46% increase in the number of patients on ORLADEYO therapy, reaching over 1,000 patients in the U.S. Despite a net loss of $53.3 million for the quarter, the outlook for ORLADEYO revenue remains strong, with expectations of at least $320 million for the full year. The firm is focused on expanding its product offerings and managing operational costs effectively.
Read more →BCRXBioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO (berotralstat)
BioCryst Pharmaceuticals announced promising results from the APeX-S clinical trial for their oral treatment ORLADEYO (berotralstat), which indicated high attack-free status among hereditary angioedema (HAE) patients over a 96-week period. The trial results were presented at the C1-inhibitor Deficiency & Angioedema Workshop in Budapest. Findings showed that patients maintained a consistently high rate of days free from attacks, regardless of age or prior treatment. Overall, the study reinforces the efficacy and tolerability of ORLADEYO as a treatment option for HAE.
Read more →BCRXBioCryst to Report First Quarter 2023 Financial Results on May 3
BioCryst Pharmaceuticals announced it will report its first quarter 2023 financial results on May 3, 2023. The company management will hold a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. BioCryst focuses on developing innovative treatments for rare diseases, with ongoing projects in the complement system and approved therapies in the U.S. and global markets.
Read more →BCRX▼ -7.1%on this newsshared move
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
BioCryst Pharmaceuticals has secured a $450 million financing commitment from Pharmakon Advisors, with plans to draw $300 million initially. The financing improves their financial position by extending repayment options to 2028, expected to coincide with growth in ORLADEYO revenues. Although no restrictive covenants are imposed, uncertainties regarding regulatory approvals and commercialization strategies pose risks. The company aims to leverage this funding to reduce market dependency and pursue further development of rare disease medicines.
Read more →BCRXBioCryst Appoints Dr. Nancy Hutson as Chair of the Board
BioCryst Pharmaceuticals has appointed Dr. Nancy Hutson as the new chair of its board of directors, effective immediately. Dr. Hutson, who has been on the board since 2012, brings over 30 years of experience in the pharmaceutical industry, including her previous role at Pfizer. Her leadership is expected to enhance the company's ability to develop innovative therapies for rare diseases. The appointment follows the tenure of Bob Ingram, noted for his effective board leadership.
Read more →BCRXBioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
BioCryst Pharmaceuticals has acknowledged the contributions of Robert A. Ingram, the company's chairman of the board, who recently passed away. Ingram had served as a board member since 2015 and chairman since 2017, significantly influencing the company's success through effective governance and diverse board recruitment. The CEO and board members expressed gratitude for his mentorship and leadership, emphasizing his impact in developing treatments for rare diseases.
Read more →BCRXBioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO (berotralstat)
BioCryst Pharmaceuticals announced positive long-term data for ORLADEYO (berotralstat), showing sustained reductions in hereditary angioedema attack rates and significant improvements in patients' quality of life. New analyses from the APeX-S and APeX-2 trials highlighted the effectiveness and tolerability of this oral therapy. These data reinforce the need for convenient prophylactic treatment options for patients with hereditary angioedema. The findings were presented at the AAAAI 2023 annual meeting in San Antonio, Texas.
Read more →BCRX▼ -15.3%on this newsshared move
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
BioCryst Pharmaceuticals reported its financial results for Q4 2022 and the full year, highlighting ORLADEYO's significant revenue growth. The company achieved ORLADEYO net revenue of $70.7 million in the fourth quarter, with expectations to surpass $320 million in 2023. However, they also reported a net loss of $71.5 million for Q4 2022, attributed to increased R&D and SG&A costs. Overall, the company expressed optimism about future sales and patient demand for ORLADEYO.
Read more →BCRXBioCryst to Report Fourth Quarter 2022 Financial Results on February 21
BioCryst Pharmaceuticals, Inc. has announced that it will report its fourth quarter 2022 financial results on February 21, 2023. The management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. The call will be accessible via phone for domestic and international callers, with an option for a live webcast and replay available on the company's investor website.
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Pharmaceuticals announced that it will present four abstracts at the 2023 AAAAI annual meeting, highlighting new data on its oral therapy ORLADEYO (berotralstat) for hereditary angioedema (HAE). These presentations will include analyses showcasing a significant reduction in attack rates and improvements in patients’ quality of life. The company aims to reinforce the therapy's value through evidence from both clinical and real-world studies. The abstracts will be available in an online supplement to The Journal of Allergy and Clinical Immunology.
Read more →BCRXBioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema
BioCryst Pharmaceuticals has initiated enrollment in the pivotal APeX-P trial for ORLADEYO (berotralstat) aimed at treating pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years. This pivotal trial seeks to evaluate ORLADEYO's pharmacokinetics and safety profile in this specific demographic. The trial will initially consist of a 12-week standard-of-care treatment followed by 48 weeks of open-label treatment. Upon completion, BioCryst plans to submit a supplemental New Drug Application for extended use of ORLADEYO in pediatric patients.
Read more →BCRXBioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO (berotralstat) in Central and Eastern Europe
BioCryst Pharmaceuticals has partnered with Swixx BioPharma to commercialize its oral therapy, ORLADEYO, in Central and Eastern Europe. This collaboration aims to address the unmet medical needs of patients with hereditary angioedema (HAE). ORLADEYO is designed to prevent HAE attacks and is indicated for patients aged 12 and older. Swixx will be responsible for commercialization in 15 markets within the region, leveraging its expertise in rare disease therapies.
Read more →BCRX▼ -10.1%on this news
BioCryst Announces Preliminary Full Year 2022 ORLADEYO (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
BioCryst Pharmaceuticals has announced preliminary unaudited net revenue results for its oral medication ORLADEYO, reporting a significant increase of 105% year-over-year for 2022, totaling $251.6 million. Looking ahead, the company projects ORLADEYO revenue for 2023 will be no less than $320 million, with ambitious peak sales expectations of $1 billion. Despite slightly underperforming in fourth quarter 2022 revenue due to lower-than-expected paid shipments and conversions, company executives remain optimistic about future growth. BioCryst is set to present further insights at the upcoming J.P. Morgan Healthcare Conference.
Read more →BCRX▼ -10.1%on this news
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
BioCryst Pharmaceuticals announced initial positive clinical data for BCX10013, an oral Factor D inhibitor, showing significant suppression of the alternative pathway in healthy volunteers. The data from phase 1 trials indicate that a single 110 mg dose achieved over 97% inhibition. The company plans to move into patient studies for conditions like paroxysmal nocturnal hemoglobinuria (PNH) by mid-2023 and aims to finalize treatment dosing for pivotal trials by year-end 2023. Additionally, BioCryst is expanding its discovery platform to develop other oral therapeutics targeting various pathways in complement-mediated diseases.
Read more →BCRXBioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
BioCryst Pharmaceuticals announced its participation in the 41st Annual J.P. Morgan Healthcare Conference to be held in San Francisco on January 10, 2023. The company's presentation is expected to highlight its progress in developing novel oral treatments for rare diseases. BioCryst is recognized for its approved product ORLADEYO®, along with other promising candidates like BCX10013. Interested stakeholders can access a live audio webcast of the presentation through the company's website.
Read more →BCRXBioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX
Read more →BCRX▼ -9.5%on this news
BioCryst to Present at JMP Securities Hematology & Oncology Summit
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET. Links to the
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary ang
Read more →BCRX▲ +10.4%on this news
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO (berotralstat), Regardless of Prior Prophylactic Therapy
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and
Read more →BCRX▼ -11.2%on this newsshared move
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021— —Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022— —Company expands complement pipeline by advancing second oral Factor D inhibitor, BCX10
Read more →BCRXBioCryst to Report Third Quarter 2022 Financial Results on November 1
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tuesday, November 1, 2022. BioCryst management will host a conference call and webc
Read more →BCRXBioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company’s significant pipeline of development candidates. Dr. Ryan Arnold h
Read more →BCRXBioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was main
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) in Saudi Arabia
RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in
Read more →BCRX▲ +23.2%on this news
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
—Q2 2022 ORLADEYO net revenue of $65.2 million— —FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for
Read more →BCRX▲ +23.2%on this news
BioCryst Resumes Enrollment in BCX9930 Clinical Program
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global
Read more →BCRXBioCryst to Report Second Quarter 2022 Financial Results on August 4
RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022. BioCryst management will host a conference call and webc
Read more →BCRXBioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO (berotralstat)
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 and APeX-S clinical trials evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylacti
Read more →BCRXBioCryst Announces ORLADEYO (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 from July 1-3, 2022, at the O
Read more →BCRXBioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America
RESEARCH TRIANGLE PARK, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin America (L
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angio
Read more →BCRXBioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in p
Read more →BCRXBioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
—Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on BCX9930 investigation— RESEARCH TRIANGLE PARK, N.C., May 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX
Read more →BCRX▼ -6%on this news
BioCryst to Report First Quarter 2022 Financial Results on May 5
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022. BioCryst management will host a conference call and webcast
Read more →BCRX▼ -37.8%on this newsshared move
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patie
Read more →BCRXBioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO (berotralstat)
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment
Read more →BCRX▼ -5.9%on this newsshared move
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients — RESEARCH TRIA
Read more →BCRX▼ -5.3%on this newsshared move
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopat
Read more →BCRXBioCryst to Report Fourth Quarter 2021 Financial Results on February 23
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022. BioCryst management will host a confer
Read more →BCRX▲ +5%on this newsshared move
BioCryst Appoints Machelle Sanders to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and accomplished pharmaceutical operations executive, Machelle Sanders, to its board o
Read more →BCRXBioCryst to Present New ORLADEYO (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary
Read more →BCRX▲ +27.9%on this news· ran to +42% by day 1
BioCryst Announces Preliminary Full Year 2021 ORLADEYO (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance
—ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021— —ORLADEYO net revenue expected to more than double in 2022 to no less than $250 million; Company expects ORLADEYO to become the market leader in HAE prophylaxis therapy with peak sales o
Read more →BCRX▼ -6.9%on this news· ran to +34% by day 3shared move
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglo
Read more →BCRXBioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 20
Read more →BCRXBioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglo
Read more →BCRXBioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK, RESEARCH TRIANGLE PARK, N.C. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- BioC
Read more →BCRX▲ +6.9%on this news
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO (berotralstat)
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from studies evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angi
Read more →BCRX▼ -18.1%on this newsshared move
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
—3Q 2021 revenue of $41.0 million— —ORLADEYO® (berotralstat) net revenue of $37.0 million— —Full year 2021 ORLADEYO net revenue expected to be $115-$120 million— RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today
Read more →BCRXBioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer. In this new role, Ms. Rosselli will lead a global team to leverage and build the
Read more →BCRXBioCryst to Report Third Quarter 2021 Financial Results on November 3
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021. BioCryst management will host a conference call and
Read more →BCRXBioCryst to Present at 2021 Cantor Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET. Links to a live audio webc
Read more →BCRXBioCryst Appoints Dr. Amy McKee to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excel
Read more →BCRXBioCryst Announces Approval of ORLADEYO (berotralstat) in United Arab Emirates
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates (UAE) has granted marketing authorization for oral, once-daily ORLADEYO® (
Read more →BCRXBioCryst Appoints Dr. Steven Galson to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former ac
Read more →BCRXBioCryst Announces Acceptance of Regulatory Applications for ORLADEYO (berotralstat) by Health Canada and Swissmedic
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accepted for review by Health Canada for the prevention of recurrent attacks in patient
Read more →BCRX▼ -13.9%on this news
BioCryst Withdraws Public Offering
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO® (berotralstat), we believe that
Read more →BCRXBioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $200 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to p
Read more →BCRX▲ +8.5%on this newsshared move
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
—2Q 2021 revenue of $50.0 million— —ORLADEYO® (berotralstat) net revenue of $28.5 million— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021,
Read more →BCRXBioCryst Appoints Vincent Milano to Board of Directors
RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors. Mr. Milano current
Read more →BCRXBioCryst to Report Second Quarter 2021 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021. BioCryst management will host a conference call and w
Read more →BCRXBioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemogl
Read more →BCRXBioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO (berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
RESEARCH TRIANGLE PARK, N.C., July 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral, once-daily ORLADEYO® (berotralstat) at the start of the APeX-2 tr
Read more →BCRXBioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with hereditary
Read more →BCRXBioCryst Launches ORLADEYO™ (berotralstat) in Germany
RESEARCH TRIANGLE PARK, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for patients with a prescription in Germany. ORLADEYO was approved by the European Medici
Read more →BCRXBioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for oral, once-daily ORLADEYO™ (be
Read more →BCRXBioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
—Q1 2021 ORLADEYO™ (berotralstat) net revenue of $10.9 million— —ORLADEYO now approved in U.S., Japan and EU— —BioCryst reaches agreement with FDA that change from baseline in hemoglobin is the primary endpoint for pivotal PNH trials of oral BCX9930 set to begin in second half
Read more →BCRXBioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) atta
Read more →BCRXBioCryst to Report First Quarter 2021 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021. BioCryst management will host a conference call and webc
Read more →BCRXBioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price listing triggers $15 million milestone payment to BioCryst— RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
Read more →BCRXBioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET. Links to a live audi
Read more →BCRXBioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
—Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-naïve patients and 83 percent of C5 inadequate response patients were transfusion-free— —Mean hemoglobin increased from 8.3 g/dL to 11.8 g/dL in treatment-naïve patients and from 8.9 g/dL to 1
Read more →BCRXBioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
RESEARCH TRIANGLE PARK, N.C., March 19, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly created position of chief research and development officer. In this role, Dr. Tha
Read more →BCRXBioCryst to Host Virtual R&D Day on March 22, 2021
RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will host a virtual R&D day on Monday, March 22, 2021 from 9:00 am to 11:00 am ET. The program will cover BioCryst’s unique, proven and
Read more →BCRXBioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (M
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
—ORLADEYO™ (berotralstat) now approved in U.S. and Japan; EU approval expected in Q2— —Dose-ranging trial of BCX9930 has fully enrolled 16 PNH patients; Data to be presented at R&D day March 22 — —Company adds $325 million in financing in Q4 2020; Year-end cash of $303 million
Read more →BCRXBioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
For investors and media only RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive
Read more →BCRXBioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. BioCryst management will host a conf
Read more →BCRXBioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is bein
Read more →BCRXBioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB Expanding Patient Population to Include Children Six Months and Older
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for RAPIVAB® (peramivir injection) expanding the patient
Read more →BCRXBioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO™ (berotralst
Read more →BCRXBioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13,
Read more →BCRXBioCryst Provides Update on Galidesivir Program
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in pa
Read more →BCRXBioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treat
Read more →BCRXBioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care— —EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support— RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLO
Read more →BCRXBioCryst to Present at JMP Securities Hematology Summit
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30
Read more →BCRXBioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250
Read more →BCRXBioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
—Data presented at the 62nd American Society of Hematology Annual Meeting— RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor under development
Read more →BCRXBioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
—Significant and sustained reduction in HAE attacks— —Oral, once-daily prophylactic option enables HAE patients to reduce burden of therapy1 — —ORLADEYO approved for adult and pediatric patients 12 years and older— RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) -
Read more →BCRXBioCryst to Present at Upcoming Virtual Investment Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual HealthCONx on Wednesday, December 2, 2020 at 12:35 p.m. ET and at the Piper Sandler 32nd Annua
Read more →BCRXBioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary angioedema (HAE) patients in th
Read more →BCRXBioCryst Presents New Data Highlighting Burden of Therapy with Current Injectable Prophylaxis Medication for HAE
—Data presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced data from a cross-sectional study a
Read more →BCRXBioCryst to Present Data at the 2020 ASH Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting being held
Read more →BCRXBioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones
—ORLADEYO™ (berotralstat) PDUFA date December 3, 2020— —Approval decisions expected in Japan in December 2020, EU in early 2021— RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for th
Read more →BCRXBiocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts and one Distinguished Industry Oral Abstract at the upcoming Annual Scientific Meeting of the American Colleg
Read more →BCRXBioCryst to Report Third Quarter 2020 Financial Results on November 5
RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020. BioCryst management will host a conference call and
Read more →BCRXBioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 22nd annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET. The conferenc
Read more →BCRXBioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones
—ORLADEYO™ (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021— —200 mg/400mg BCX9930 data from treatment-naïve PNH patients expected in Q3 2020, 200 mg/400mg data from poor-responders to C5 inhibitors expected by year end 2020 — —Information from P
Read more →BCRXBioCryst to Report Second Quarter 2020 Financial Results on August 6
RESEARCH TRIANGLE PARK, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020. BioCryst management will host a conference call and w
Read more →BCRXBioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States
RESEARCH TRIANGLE PARK, N.C., June 09, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients with hereditary
Read more →BCRXBioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in fu
Read more →BCRXBioCryst to Present at Jefferies Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m. ET. Links to a live audio webcast and
Read more →BCRXBioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share. In addition,
Read more →BCRXBioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress
RESEARCH TRIANGLE PARK, N.C., May 26, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an oral, once-daily therapy under regulatory review in the United States, Japan and the Eu
Read more →BCRXBioCryst Celebrates HAE Patients with HAE Global Walk
RESEARCH TRIANGLE PARK, N.C., May 15, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced companywide activities in support of hae day :-) 2020, a global awareness day for hereditary angioedema (HAE). BioCryst stands in solidarity with the HAE c
Read more →BCRXBioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in galidesivir trial in COVID-19 patients in Brazil— RESEARCH TRIANGLE PARK, N.C., M
Read more →BCRXBioCryst to Report First Quarter 2020 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2020 financial results on Wednesday, May 6, 2020. BioCryst management will host a conference call and web
Read more →BCRXBioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
RESEARCH TRIANGLE PARK, N.C., April 09, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antivi
Read more →BCRXBioCryst to Present at 19th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 10:00 a.m. ET. The conference is being cond
Read more →BCRXBioCryst Appoints Anthony Doyle Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C., April 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Anthony Doyle as senior vice president and chief financial officer (CFO). Mr. Doyle joins BioCryst from Worldwide Clinical Trials, a
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones
—Berotralstat NDA accepted by FDA; PDUFA date December 3, 2020— —JNDA accepted by PMDA under Sakigake timeline; approval expected 2H 2020— —PNH proof of concept data with oral Factor D inhibitor, BCX9930, expected 2Q 2020— RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NE
Read more →BCRXBioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930
RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). These patients were naïve to ec
Read more →BCRXBioCryst to Present at Barclays Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Tuesday, March 10, 2020 at 8:00 a.m. ET. Links to a
Read more →BCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 333,000 shares of B
Read more →BCRXBioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present abstracts with new data on berotralstat (BCX7353), an oral, once daily therapy under regulatory review in the United States a
Read more →BCRXBioCryst Appoints Alan G. Levin to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has appointed former Pfizer chief financial officer (CFO), Alan G. Levin, to its board of directors (BOD). In addition to his 20-year ca
Read more →BCRXBioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020. BioCryst management will host a conferen
Read more →BCRXBioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of
Read more →BCRXBioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has submitted a new drug application (JNDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for approval of oral, once daily ber
Read more →BCRXBioCryst Strengthens Commercial Rare Disease Leadership
RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States. Mr. Gayer join
Read more →BCRXBioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for hereditary angioedema (HAE), and BCX9930, an oral Factor D inhibit
Read more →BCRXBioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 20,000 shares of Bi
Read more →BCRXBioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 5:00 p.m. ET. Links
Read more →BCRXBioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral, once daily berotralstat (BCX7353) for the pre
Read more →BCRXBioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock, including 5,689,655 shares sold pursuant to the exercise in fu
Read more →BCRXBioCryst Prices Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock, offered at a price to the public of $1.45 per share. The gross p
Read more →BCRXBioCryst Commences Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $55 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the un
Read more →BCRXBioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones
—New drug application for oral, once-daily BCX7353 for prevention of hereditary angioedema attacks on-track for submission to FDA in Q4 2019— —Data from proof of concept study in PNH patients with oral Factor D inhibitor, BCX9930, expected in 1H 2020— RESEARCH TRIANGLE PARK, N
Read more →BCRXBioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
—Agreement includes up to $42 million of upfront and potential milestone payments plus royalties on net sales— —JNDA submission to PMDA on track for Q1 2020— —Deal leverages Torii’s proven track record to deliver innovative therapies to Japanese patients— RESEARCH TRIANGLE PAR
Read more →BCRXBioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva
—BCX9250 significantly suppressed heterotrophic ossification in preclinical studies— —Urgent medical need with no approved treatments for FOP — —Phase 1 data expected in 2H 2020— RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Na
Read more →BCRXBioCryst to Provide Commercial Update and Report Third Quarter 2019 Financial Results on November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will provide a commercial update and report its third quarter 2019 financial results on Wednesday, November 6, 2019. BioCryst management
Read more →BCRXBioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and part 2 MAD data support advancement of program into part 3 proof of concept (PoC) s
Read more →BCRXBioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on Friday, October 4, 2019 at 12:35 p.m. ET. Links to a live audio w
Read more →BCRXBioCryst Appoints Helen Thackray, M.D., to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to its board of directors. Dr. Thackray currently serves as chie
Read more →BCRXBioCryst to Present at H.C. Wainwright Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Investment Conference in New York on Monday, September 9, 2019 at 9:10 a.m. ET. Links to a li
Read more →BCRXBioCryst Reports Second Quarter 2019 Financial Results
—New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral Factor D inhibitor, BCX9930, expected in Q4 2019— RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE
Read more →BCRXBioCryst to Report Second Quarter 2019 Financial Results on August 6
RESEARCH TRIANGLE PARK, N.C., July 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial results on Tuesday, August 6, 2019. BioCryst management will host a conference call and we
Read more →BCRXBioCryst Appoints Megan Sniecinski Chief Business Officer
RESEARCH TRIANGLE PARK, N.C., July 01, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Megan Sniecinski as chief business officer. Ms. Sniecinski joins BioCryst from PTC Therapeutics, where she served as senior vice presi
Read more →BCRXBiocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the c
Read more →BCRXBioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
RESEARCH TRIANGLE PARK, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of hereditary angioedema
Read more →BCRXBioCryst to Present at Bank of America Merrill Lynch Health Care Conference
RESEARCH TRIANGLE PARK, N.C., May 10, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 15, 2019 at 1:00 p.m. ET. Links to
Read more →BCRXBioCryst Completes Phase 1 Clinical Trial of Galidesivir
RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. In the trial, gal
Read more →BCRXBioCryst Reports First Quarter 2019 Financial Results
—Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial of oral BCX7353 for acute treatment of HAE attacks to commence this summer— —Phase 1 trial of oral Fa
Read more →BCRXBioCryst to Report First Quarter 2019 Financial Results on May 8
RESEARCH TRIANGLE PARK, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial results on Wednesday, May 8, 2019. BioCryst management will host a conference call and web
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2018 Financial Results
—APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm safety and efficacy profile of oral 750 mg BCX7353 for upcoming Phase 3 trial in acute treatment of HAE
Read more →BCRXBioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
—BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervous system — —Patients currently limited to intravenous (IV) infusion therapy, or
Read more →BCRXBioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
—Based on ZENITH-1 data, company plans to commence Phase 3 trial of single-dose 750 mg oral BCX7353 for acute treatment of hereditary angioedema (HAE) attacks in summer 2019— —Data show excellent clinical dose response in ZENITH-1, as predicted by pK data— —BCX7353 well-tolerat
Read more →BCRXBioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018 financial results on Monday, March 4, 2019. BioCryst management will host a conference
Read more →BCRXBioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
—New loan facility increases to $50 million to further extend cash runway— —Additional $30 million available at company option following positive Phase 3 APeX-2 data— —Another $20 million available at company option following NDA approval of BCX7353 for HAE prophylaxis— RESEAR
Read more →BCRXBioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the ZENITH-1 study at the upcoming annual meeting of the American Academy of Allergy, Asth
Read more →BCRXBioCryst Appoints Steve Aselage to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Steve Aselage to its board of directors. Mr. Aselage most recently served as chief executive officer of Retrophin Pharmaceu
Read more →BCRXBioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 1:30 p.m. ET. Links t
Read more →BCRXBioCryst Initiates Phase 1 Clinical Trial of Galidesivir
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers.
Read more →BCRXBioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. Ms. Heggie currently serves as senior vice president, head of Europe, Canada, Mid
Read more →BCRXBioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute tr
Read more →BCRXBioCryst Reports Third Quarter 2018 Financial Results
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2018. “With enrollment in APe
Read more →BCRXBioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) Nov
Read more →BCRXBioCryst to Report Third Quarter 2018 Financial Results on November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial results on Tuesday, November 6, 2018. BioCryst management will host a conference call and we
Read more →BCRXBioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, October 2, 2018 at 1:40 p.m. ET. Links to a l
Read more →BCRXBioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever
RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5
Read more →BCRXBioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
—Safety and efficacy data support advancement of 750 mg dose as first oral therapy for acute HAE attacks— RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced initial results from the ZENITH-1 trial showing
Read more →BCRXBioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, 2018 at 2:35 p.m. ET. Links to a live audio
Read more →BCRXBioCryst Reports Second Quarter 2018 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2018. “Building on the clear direction from our shareholders and a strong conviction in the medica
Read more →BCRXBioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in fu
Read more →BCRXBioCryst Pharmaceuticals Prices Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share. The gross pr
Read more →BCRXBioCryst Pharmaceuticals Commences Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $50 m
Read more →BCRXBioCryst to Announce Second Quarter 2018 Financial Results on August 7
RESEARCH TRIANGLE PARK, N.C., July 27, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2018 financial results will be reported on Tuesday, August 7, 2018. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine
73.8% reduction in attacks with significant benefits in quality of life from once-daily oral dosing of BCX7353 125 mg RESEARCH TRIANGLE PARK, N.C., July 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development
Read more →BCRXBioCryst Provides Update on Strategy, Pipeline and Outlook
BioCryst Provides Update on Strategy, Pipeline and Outlook RESEARCH TRIANGLE PARK, N.C. - July 11, 2018 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company"), a pharmaceutical company focused on the development and commercialization of treatments for rare
Read more →BCRXBioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals
BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals RESEARCH TRIANGLE PARK, N.C. - July 10, 2018 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst") today announced that it has terminated the previously announced merger agreemen
Read more →BCRXBioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan
BCX7353 continues development under Sakigake designation RESEARCH TRIANGLE PARK, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, toda
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conf
Read more →BCRXBioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress
RESEARCH TRIANGLE PARK, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced the presentation of additional analyses of the A
Read more →BCRXBioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
EMA Grants Orphan Designation UK MHRA Grants Promising Innovative Medicine Designation RESEARCH TRIANGLE PARK, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treat
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the Jefferies 2018 Global Healthcare C
Read more →BCRXBioCryst Reports First Quarter 2018 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 08, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2018. “We are off to a strong start in 2018 as we continue to make progress advancing all our HAE d
Read more →BCRXBioCryst Receives European Medicines Agency Approval for ALPIVAB™ for the Treatment of Influenza
RESEARCH TRIANGLE PARK, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the European Medicines Agency (EMA) has app
Read more →BCRXBioCryst to Announce First Quarter 2018 Financial Results on May 8
RESEARCH TRIANGLE PARK, N.C., April 26, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its first quarter 2018 financial results will be reported on Tuesday, May 8, 2018. BioCryst will host a conference call and webcast at 11:00 a.m. Ea
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced they will be presenting at the 17th Annual Needham Healthcare Confer
Read more →BCRXBioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., March 15, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD) as a
Read more →BCRXBioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first patient in APeX-S, a long-term safety trial evaluating two dosage strengths of BCX7353 administered orally once-daily as a preventi
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
Provide Update on Key Benefits of Pending Merger and Comprehensive Evaluation of Strategic Opportunities Leading Up to Definitive Merger Agreement BioCryst and Idera Boards of Directors Unanimously Recommend Respective Stockholders Vote “FOR” the Proposed Merger RESEARCH TRIANG
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2017 Financial Results Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc. Research Triangle Park, North Carolina
BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc. Research Triangle Park, North Carolina - February 27, 2018 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financia
Read more →BCRXBioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018. BioCryst will host a conference call and webc
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will be presenting at two upcoming healthcare-focused investor conferences. The compan
Read more →BCRXBioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918 -
Read more →BCRXExecution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this Agreement ) is entered into as of
VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this Agreement ) is entered into as of January 21, 2018, by and between Biocryst Pharmaceuticals, Inc., a Delaware corporation ( Boat ), and 667, L.P. and Baker Brothers Life Sciences, L.P. (each, a Stockholder and,
Read more →BCRXBioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it has advanced a program exploring activin receptor-like kinase-2 (ALK2) inhibitors for treatment of Fibrodysplasia Ossificans Progressiva (FOP). Inv
Read more →BCRXBioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 36th annual J.P.
Read more →BCRXBioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 29th Annual Piper
Read more →BCRXBioCryst Reports Third Quarter 2017 Financial Results
BCX7353 Phase 3 program agreed with FDA and EMA U.S. Orphan Drug designation for BCX7353 received from FDA RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the third quarter ended
Read more →BCRXBioCryst to Present at the Jefferies 2017 London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Jefferies 2017 Lo
Read more →BCRXBioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that results from its successful Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE) will be presented at the American College of Allergy, Asthma
Read more →BCRXBioCryst to Announce Third Quarter 2017 Financial Results on November 7
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017. BioCryst will host a conference call and webcast at 11:00 a.m
Read more →BCRXBioCryst Announces RAPIVAB (peramivir injection) and Galidesivir Presentations at IDWeek 2017™
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that interim results from a clinical trial of a single IV dose of RAPIVAB® (peramivir injection) for the treatment of pediatric influenza and results from
Read more →BCRXBioCryst’s RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food and Drug Admin
Read more →BCRXBioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
73% Reduction in Overall Attack Frequency at 125mg Dose (p<0.001) FDA and EMA Meetings Planned for Fourth Quarter 2017 to Finalize Phase 3 RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced final results
Read more →BCRXBioCryst Announces Corporate Update Conference Call and Webcast
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company will host a conference call on Tuesday, September 5, 2017, at 9:00 a.m. Eastern Time to provide an update on the Company’
Read more →BCRXBioCryst to Present at Three Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the following investo
Read more →BCRXBioCryst Reports Second Quarter 2017 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2017. “We are excited by the positive results previously reported in Parts 1 and 2 of the APeX-1 c
Read more →BCRXBioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353 given as a single
Read more →BCRXBioCryst to Announce Second Quarter 2017 Financial Results on August 7
RESEARCH TRIANGLE PARK, N.C., July 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2017 financial results will be reported on Monday, August 7, 2017. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst to Present at the JMP Securities 2017 Life Sciences Conference
RESEARCH TRIANGLE PARK, N.C., June 13, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the JMP Securities 20
Read more →BCRXBioCryst Announces RAPIVAB Pediatric sNDA Acceptance
RESEARCH TRIANGLE PARK, N.C., June 05, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric indication of RAPIVAB
Read more →BCRXBioCryst to Present at the Jefferies 2017 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 31, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Jefferies 2017 Glo
Read more →BCRXBioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
RESEARCH TRIANGLE PARK, N.C., May 25, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed t
Read more →BCRXBioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Bank of America Me
Read more →BCRXBioCryst Reports First Quarter 2017 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2017. “We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353
Read more →BCRXBioCryst to Announce First Quarter 2017 Financial Results May 4
RESEARCH TRIANGLE PARK, N.C., April 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
RESEARCH TRIANGLE PARK, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today plans to explore a new oral liquid formulation
Read more →BCRXBioCryst Announces Mundipharma Receives Approval for Mundesine in Japan
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cel
Read more →BCRXBioCryst to Present at the 16th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 16th Annual Needham Healthcare
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2016 Financial Results
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier today, BioCryst announced positi
Read more →BCRXBioCryst Reports Positive Interim Results from its APeX-1 Trial
Reduction of 63% in overall attack rate in HAE patients with severe disease (p=0.006) RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from an interim analysis of its Phase 2 APeX-1 trial in here
Read more →BCRXBioCryst to Announce Fourth Quarter and Year End 2016 Financial Results February 27
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017. BioCryst will host a conference call and webcas
Read more →BCRXBioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency
RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today that the European Medicines Agency (EMA) has ac
Read more →BCRXBioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza
RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that Health Canada has approved RAPIVAB® (peram
Read more →BCRXBioCryst to Present at the J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s development programs at the 35th
Read more →BCRXBioCryst to Present at the Piper Jaffray Healthcare Conference November 30
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 28th Annual Piper Jaffray Health
Read more →BCRXBioCryst Reports Third Quarter 2016 Financial Results
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2016. “Our company’s primary focus is on the execution of the APeX-1 trial of BCX7353,” said J
Read more →BCRXBioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a study of galidesivir (formerly BCX4430) administered to Rhesus monkeys infected with Zika virus (ZIKV) will be presented as a late-brea
Read more →BCRXBioCryst to Announce Third Quarter 2016 Financial Results November 7
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2016 financial results will be released on Monday, November 7, 2016. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst Closes $23 Million Senior Credit Facility
Cash runway extended to early 2018; Facility to be repaid with RAPIVAB revenues RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Company has closed a $23 million Senior Credit Facility with Mid
Read more →BCRXBioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced positive results from a proof-of-concept study of its broad spectrum antiviral, BCX4430, for the delayed treatment of Ebola virus infection in rhesus maca
Read more →BCRXBioCryst to Present at the Baird 2016 Global Healthcare Conference September 8
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at Baird’s 2016 Global Healthcare Confe
Read more →BCRXBioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (HAE). “We are very pleased th
Read more →BCRXBioCryst Reports Second Quarter 2016 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2016. “We continue to make progress, and have initiated subject screening to start the APeX-1 tria
Read more →BCRXBioCryst to Announce Second Quarter 2016 Financial Results August 4
RESEARCH TRIANGLE PARK, N.C., July 21, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2016 financial results will be released on Thursday, August 4, 2016. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
RESEARCH TRIANGLE PARK, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has provided additional funding for efficacy studies of BCX4430 in non-human primate
Read more →BCRXBioCryst to Present at Two Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 26, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the following investor conferences:
Read more →BCRXBioCryst Reports First Quarter 2016 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 05, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016. “We are currently working through the start-up activities for the APeX-1 trial of BCX7353 for
Read more →BCRXBioCryst to Announce First Quarter 2016 Financial Results May 5
RESEARCH TRIANGLE PARK, N.C., April 21, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Ea
Read more →BCRXBioCryst to Present at Barclays Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., March 09, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s development programs at the Barc
Read more →BCRXBioCryst Reports Fourth Quarter & Full Year 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2015. “In 2015, we gained clarity on both of our HAE drug candidates and brought
Read more →BCRXBioCryst to Announce Fourth Quarter & 2015 Financial Results February 23
RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth quarter and full year 2015 financial results will be released on Tuesday, February 23, 2016. BioCryst will host a conference call and webca
Read more →BCRXBioCryst Announces Results From OPuS-2
RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the pr
Read more →BCRXBioCryst To Present At Two Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company at the following investor conferences: The 27th Annual Pip
Read more →BCRXBioCryst Reports Third Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2015. "The completion of enrollment of our OPuS-2 trial of avoralstat and the successful outcom
Read more →BCRXBioCryst to Present at the Jefferies Autumn 2015 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 4, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Jefferies Autumn 2015
Read more →BCRXBioCryst to Announce Third Quarter 2015 Financial Results November 5
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2015 financial results will be released on Thursday, November 5, 2015. BioCryst will host a conference call and webcast at 11:00 a.m
Read more →BCRXBioCryst Announces Completion of Patient Enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE
RESEARCH TRIANGLE PARK, N.C., Oct. 8, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it has completed enrollment in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered avoralstat
Read more →BCRXBioCryst Announces Successful Phase 1 Clinical Trial of BCX7353
Advancing once-daily BCX7353 into a Phase 2 trial in hereditary angioedema patients RESEARCH TRIANGLE PARK, N.C., Oct. 8, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the randomized, placebo-controlled, Phase 1 clinical trial of oral
Read more →BCRXBioCryst Reports Second Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 7, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2015. "During the second quarter, we continued to make steady progress in executing our strategy an
Read more →BCRXBioCryst to Announce Second Quarter 2015 Financial Results August 7
RESEARCH TRIANGLE PARK, N.C., July 23, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2015 financial results will be released on Friday, August 7, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. E
Read more →BCRXBioCryst to Present at the JMP Securities Life Sciences Conference
RESEARCH TRIANGLE PARK, N.C., June 18, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate summary and update regarding the Company's programs at the JMP Securities Life Sciences
Read more →BCRXBioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited
RESEARCH TRIANGLE PARK, N.C., June 17, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) and CSL Limited (ASX:CSL) (USOTC:CSLLY) - BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare
Read more →BCRXBioCryst to Present at the Jefferies 2015 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 26, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate summary and update regarding the Company's programs at the Jefferies 2015 Healthcare Conf
Read more →BCRXBioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteer
Read more →BCRXBioCryst Reports First Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 8, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2015. "We look forward to an exciting second half of 2015, when we anticipate reporting data from tw
Read more →BCRXBioCryst to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 5, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate summary and update regarding the Company's clinical programs at the Bank of America Merril
Read more →BCRXBioCryst to Announce First Quarter 2015 Financial Results May 8
RESEARCH TRIANGLE PARK, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its first quarter 2015 financial results will be released on Friday, May 8, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. East
Read more →BCRXBioCryst to Present at the Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 7, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's development programs at the 14th Annual Needham Healthcar
Read more →BCRXBioCryst Awarded BCX4430 Advanced Development Contract
RESEARCH TRIANGLE PARK, N.C., March 31, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services' Office of the Assistant S
Read more →BCRXBioCryst Reports Fourth Quarter & Full Year 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2014. "We are proud of our 2014 achievements; most notably our successful comple
Read more →BCRXBioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter 2014 financial results will be released on Wednesday, February 18, 2015. BioCryst will host a conference call and webcast at 11:00 a
Read more →BCRXBioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for orphan dru
Read more →BCRXBioCryst to Present at J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at the 33rd a
Read more →BCRXBioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer
RESEARCH TRIANGLE PARK, N.C., Jan. 5, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced the appointment of Ms. Lynne Powe
Read more →BCRXBioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Dec. 23, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BCX4161 for the prevention of acute attacks of angioedema in patie
Read more →BCRXBioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection
RESEARCH TRIANGLE PARK, N.C., Dec. 23, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced results from a proof-of-concept study of its broad spectrum antiviral BCX4430 for the treatment of experimental Ebola virus infection in rhesus macaques, c
Read more →BCRXBioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Admi
Read more →BCRXBioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Dec. 18, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX416
Read more →BCRXBioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses
RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate intramuscular (I.M.) administration of BCX4430 in he
Read more →BCRXBioCryst Reports Third Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., Nov. 6, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2014. "The primary focus of our Company continues to be our oral kallikrein inhibitor program f
Read more →BCRXBioCryst to Announce Third Quarter 2014 Financial Results November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its third quarter 2014 financial results will be released on Thursday, November 6, 2014. BioCryst will host a conference call and webcast at 11:00 a.m
Read more →BCRXBioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress
RESEARCH TRIANGLE PARK, N.C., Oct. 7, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that results from its successful OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hered
Read more →BCRXBioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised two additional options under its contract, which provides for GMP dru
Read more →BCRXBioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
RESEARCH TRIANGLE PARK, N.C., Sept. 6, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced trial results related to RAPIVAB (peramivir injection), a neuraminidase inhibitor (NAI) for the treatment of influenza at the Interscience Conference on An
Read more →BCRXBioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies
RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced its participation in a consultation on potential Ebola therapies and vaccines hosted by the World Health Organization (WHO). The meeting is scheduled to ta
Read more →BCRXBioCryst to Present at Rodman & Renshaw Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the Rodman & Renshaw 16th Annua
Read more →BCRXBioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
RESEARCH TRIANGLE PARK, N.C., Sept. 2, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the presentation of trial results related to intravenous (I.V.) peramivir for the treatment of influenza at the Interscience Conference on Antimicrobial Ag
Read more →BCRXBioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease
RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract modification for an additional $2.4 million to BioCryst to co
Read more →BCRXBioCryst Reports Second Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2014. "The successful OPuS-1 Phase 2 clinical trial of BCX4161 in patients with hereditary angioede
Read more →BCRXBioCryst to Announce Second Quarter 2014 Financial Results August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its second quarter 2014 financial results will be released on Tuesday, August 5, 2014. BioCryst will host a conference call and webcast at 11:00 a.m.
Read more →BCRXBioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering
RESEARCH TRIANGLE PARK, N.C., June 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the completion of an underwritten public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the full exercise of
Read more →BCRXBioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 for the Prophylactic Treatment of Hereditary Angioedema
Significant reduction in HAE attacks by 0.45 per week versus placebo (p<0.001) RESEARCH TRIANGLE PARK, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept P
Read more →BCRXBioCryst to Announce Results From the BCX4161 OPuS-1 Phase 2 Trial for Hereditary Angioedema May 27
RESEARCH TRIANGLE PARK, N.C., May 24, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that management plans to report results for the OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in pati
Read more →BCRXBioCryst to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 9, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the Bank of America Merrill Lynch
Read more →BCRXBioCryst Reports First Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2014. "We have completed enrollment in the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4
Read more →BCRXBioCryst to Announce First Quarter 2014 Financial Results May 8
RESEARCH TRIANGLE PARK, N.C., April 28, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its first quarter 2014 financial results will be released on Thursday, May 8, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Ea
Read more →BCRXBioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection
RESEARCH TRIANGLE PARK, N.C., March 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal mod
Read more →BCRXBioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results
RESEARCH TRIANGLE PARK, N.C., March 1, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 c
Read more →BCRXBioCryst Reports Fourth Quarter and Full Year 2013 Financial Results
RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2013. "Since our last quarterly results update, we have initiated the OPuS-1 Pha
Read more →BCRXBioCryst Announces Peramivir NDA Acceptance by the FDA
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Admi
Read more →BCRXBioCryst to Announce Fourth Quarter and 2013 Financial Results February 26
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter and full year 2013 financial results will be released on Wednesday, February 26, 2014. BioCryst will host a conference call and web
Read more →BCRXBioCryst Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, June 30, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc. (Nasdaq:BCRX). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educat
Read more →BCRXBioCryst Pharmaceuticals, Inc. (BCRX) Chairman and CEO to Ring the NASDAQ Stock Market Opening Bell
MEDIA ADVISORY, Aug. 21, 2006 (PRIMEZONE) -- Dr. Charles Bugg, Chairman and Chief Executive Officer of BioCryst Pharmaceuticals, Inc. (BCRX), will preside over the opening bell to celebrate its 20-year business anniversary. NASDAQ MarketSite - 4 Times Square - 43rd & Broadway
Read more →Competitive Position
How BCRX ranks across every disease it competes inCompetitive Position is a premium feature
See how BCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial